Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07463599Phase 1Recruiting

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

Role: collaborator

NCT07144254Phase 1Recruiting

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

Role: collaborator

NCT05797805Phase 1Recruiting

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

Role: lead

NCT03459469Phase 1Completed

Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059

Role: lead

All 4 trials loaded